{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:03:54Z","timestamp":1778807034654,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s40273-015-0375-7","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T09:46:11Z","timestamp":1453283171000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["EQ-5D Utilities in Chronic Spontaneous\/Idiopathic Urticaria"],"prefix":"10.1007","volume":"34","author":[{"given":"Emma","family":"Hawe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-5417","authenticated-orcid":false,"given":"Donald E.","family":"Stull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"issue":"7","key":"375_CR1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","volume":"69","author":"T Zuberbier","year":"2014","unstructured":"Zuberbier T, Aberer W, Asero R, et al. The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868\u201387.","journal-title":"Allergy"},{"issue":"10","key":"375_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ddg.12194_suppl","volume":"11","author":"M Maurer","year":"2013","unstructured":"Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971\u20138. doi: 10.1111\/ddg.12194 .","journal-title":"J Dtsch Dermatol Ges"},{"key":"375_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria: a GA2LEN Task Force report. Allergy. 2011;66:317\u201330.","journal-title":"Allergy"},{"issue":"6","key":"375_CR4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40271-015-0145-9","volume":"8","author":"MM Balp","year":"2015","unstructured":"Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient\u2019s perspective: a survey in five European countries. Patient. 2015;8(6):551\u20138.","journal-title":"Patient"},{"issue":"2","key":"375_CR5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","volume":"136","author":"BF O\u2019Donnell","year":"1997","unstructured":"O\u2019Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197\u2013201.","journal-title":"Br J Dermatol"},{"issue":"2","key":"375_CR6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2133.2005.06976.x","volume":"154","author":"P Staubach","year":"2006","unstructured":"Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154(2):294\u20138.","journal-title":"Br J Dermatol"},{"key":"375_CR7","unstructured":"Stull DE, McBride D, Gimenez-Arnau A, et al. Validation of chronic spontaneous\/idiopathic urticaria (CSU\/CIU) health states using weekly Urticaria Activity Score (UAS7) and Dermatology Life Quality Index (DLQI) [poster]. American Academy of Dermatology Annual Meeting, San Francisco, March 2015. RTI Health Solutions. 2015. https:\/\/www.rtihs.org\/publications\/validation-chronic-spontaneousidiopathic-urticaria-csuciu-health-states-using-weekly . Accessed 10 Oct 2015."},{"key":"375_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-0-387-78665-0_5","volume-title":"Handbook of disease burdens and quality of life measures","author":"N Gusi","year":"2010","unstructured":"Gusi N, Olivares PR, Rajendram R. The EQ-5D health-related quality of life questionnaire. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York: Springer; 2010. p. 87\u201399."},{"key":"375_CR9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736\u201341.","journal-title":"BMJ"},{"key":"375_CR10","unstructured":"EuroQol Research Foundation. EuroQoL EQ-5D-5L. EuroQol Research Foundation. 2015. http:\/\/www.euroqol.org\/faqs\/eq-5d-5l.html . Accessed 1 Oct 2015."},{"key":"375_CR11","unstructured":"Stull DE, McBride D, Gimenez-Arnau A, et al. Categorical health states in chronic spontaneous urticaria (CSU) based on the weekly Urticaria Activity Score (UAS7): are they distinct, discriminative, and reproducible? [poster]. ISPOR 17th Annual European Congress, Amsterdam, November 2014. RTI Health Solutions. 2014. https:\/\/www.rtihs.org\/sites\/default\/files\/ISPOR%202014_CSU%20Health%20states%20Final%20version%20for%20print_862_6th%20Nov.pdf . Accessed 6 Oct 2015."},{"key":"375_CR12","first-page":"33","volume":"66","author":"S Saini","year":"2011","unstructured":"Saini S, Rosen K, Hsieh H, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic urticaria who remain symptomatic despite concomitant H1 antihistamine therapy: results of a phase\u00a02 trial [abstract]. 30th Congress of the European Academy of Allergy and Clinical Immunology, Istanbul,\u00a0June\u00a02011. Allergy. 2011;66:33.","journal-title":"Allergy."},{"key":"375_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924\u201335.","journal-title":"N Engl J Med"},{"key":"375_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"375_CR15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","volume":"105","author":"SD Mathias","year":"2010","unstructured":"Mathias SD, Dreskin SC, Kaplan A, et al. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2010;105(2):142\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"375_CR16","unstructured":"National Institute for Health and Care Excellence. Omalizumab for previously treated chronic spontaneous urticaria. NICE technology appraisal guidance [TA339]. National Institute for Health and Care Excellence. 2015. https:\/\/www.nice.org.uk\/guidance\/ta339\/chapter\/1-guidance . Accessed 6 Oct 2015."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0375-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-015-0375-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-015-0375-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:50Z","timestamp":1553612870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-015-0375-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s40273-015-0375-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}